Athira Pharma’s IPO


Wilson Sonsini Goodrich & Rosati advised Athira Pharma, Inc. on the deal.

Athira Pharma, Inc., a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration priced its initial public offering of 12 million shares of its common stock at $17.00 per share. All shares were offered by Athira. The gross proceeds are expected to be $204 million, before deducting underwriting discounts and commissions and estimated offering expenses.

The shares began trading on Friday September 18, 2020, on the Nasdaq Global Select Market under the ticker symbol “ATHA.” The sale of the 12 million shares closed on September 22, 2020. Athira also granted the underwriters a 30-day option to purchase up to an additional 1.8 million shares of its common stock at the initial public offering price, less underwriting discounts and commissions.

The offering was led by Goldman Sachs & Co. LLC, Jefferies, and Stifel, with JMP Securities acting as co-manager.

Based in Seattle, Washington, Athira Pharma is in late-stage clinical development for its lead therapeutic candidate called ATH-1017, a drug being developed for the treatment of Alzheimer’s disease.

The Wilson Sonsini corporate team advising Athira includes partners Michael Nordtvedt (Picture), Bryan King, and Donna Petkanics, associates Laura Duncan, Ashley Schmidt, and Nate Hickner, and senior paralegal Barbara Mery.

Involved fees earner: Laura Duncan – Wilson Sonsini Goodrich & Rosati; Nate Hickner – Wilson Sonsini Goodrich & Rosati; Bryan King – Wilson Sonsini Goodrich & Rosati; Barbara Mery – Wilson Sonsini Goodrich & Rosati; Michael Nordtvedt – Wilson Sonsini Goodrich & Rosati; Donna Petkanics – Wilson Sonsini Goodrich & Rosati; Ashley Schmidt – Wilson Sonsini Goodrich & Rosati;

Law Firms: Wilson Sonsini Goodrich & Rosati;

Clients: Athira Pharma Inc;

Author: Ambrogio Visconti